Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Ashraf M, Shokrollahi S, Pisig AU, Sampani K, Abdelal O, Cavallerano JD, Robertson G, Fleming A, Van Hemert J, Pitoc CM, Sun JK, Aiello LP, Silva PS. Retinal vascular caliber association with nonperfusion and diabetic retinopathy severity depends on vascular caliber measurement location. Ophthalmol Retina. 2021 Jun;5(6):571-9. doi: 10.1016/j.oret.2020.09.003
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Maclean EN, Stone IS, Ceelen F, Garcia-Albeniz X, Sommer WH, Petersen SE. Reporting standards in cardiac MRI, CT, and SPECT diagnostic accuracy studies: analysis of the impact of STARD criteria. Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):691-700. doi: 10.1093/ehjci/jet277